HK1201209A1 - Therapeutic agent for diabetes - Google Patents

Therapeutic agent for diabetes Download PDF

Info

Publication number
HK1201209A1
HK1201209A1 HK15101890.2A HK15101890A HK1201209A1 HK 1201209 A1 HK1201209 A1 HK 1201209A1 HK 15101890 A HK15101890 A HK 15101890A HK 1201209 A1 HK1201209 A1 HK 1201209A1
Authority
HK
Hong Kong
Prior art keywords
group
therapeutic
diabetes
prophylactic agent
acid
Prior art date
Application number
HK15101890.2A
Other languages
English (en)
Chinese (zh)
Inventor
久留郎
久留一郎
辻本俊亮
白倉尚
白仓尚
平光伸也
Original Assignee
帝人制药株式会社
国立大学法人鸟取大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 帝人制药株式会社, 国立大学法人鸟取大学 filed Critical 帝人制药株式会社
Publication of HK1201209A1 publication Critical patent/HK1201209A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15101890.2A 2012-01-27 2013-01-25 Therapeutic agent for diabetes HK1201209A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-015351 2012-01-27
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
HK1201209A1 true HK1201209A1 (en) 2015-08-28

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101890.2A HK1201209A1 (en) 2012-01-27 2013-01-25 Therapeutic agent for diabetes

Country Status (15)

Country Link
US (1) US20150005506A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2808018B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5924699B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20140134266A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104066430A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR089812A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013212865A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014017902A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2862602A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1201209A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN05972A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014008484A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2014134845A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW201334779A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013111870A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
US11344539B2 (en) 2016-02-19 2022-05-31 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69122084T2 (de) * 1990-11-30 1997-04-03 Teijin Ltd., Osaka 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
EP1778261A4 (en) * 2004-07-21 2010-08-11 Univ Florida COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE
JP2009501795A (ja) * 2005-07-21 2009-01-22 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法
US20070167454A1 (en) 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
JP2009516691A (ja) * 2005-11-21 2009-04-23 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド Ｑｔ間隔延長およびこれに伴う疾病の治療
JP2007210978A (ja) 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
ME01996B (me) * 2007-11-27 2015-05-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije, te postupci za upotrebu
AU2009252166B9 (en) * 2008-03-31 2014-02-13 C & C Research Laboratories Heterocyclic derivatives
US8410154B2 (en) * 2008-04-30 2013-04-02 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
MX2010012656A (es) * 2008-05-22 2010-12-20 Squibb Bristol Myers Co Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo.
US20110257202A1 (en) * 2008-10-19 2011-10-20 Richard J Johnson Therapeutic Compositions and Methods for Treating Chronic Kidney Disease Associated with a Metabolic Imbalance
WO2011022757A1 (en) * 2009-08-24 2011-03-03 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
MX361138B (es) * 2010-06-16 2018-11-28 Takeda Pharmaceuticals Usa Inc Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.
SG186798A1 (en) * 2010-06-25 2013-02-28 Teijin Pharma Ltd Sustained-release therapeutic agent for hypertension and renal dysfunction

Also Published As

Publication number Publication date
JPWO2013111870A1 (ja) 2015-05-11
MX2014008484A (es) 2014-10-14
AR089812A1 (es) 2014-09-17
US20150005506A1 (en) 2015-01-01
EP2808018A1 (en) 2014-12-03
BR112014017902A2 (pt) 2017-08-22
EP2808018B1 (en) 2018-03-14
AU2013212865A1 (en) 2014-08-14
WO2013111870A1 (ja) 2013-08-01
TW201334779A (zh) 2013-09-01
KR20140134266A (ko) 2014-11-21
JP5924699B2 (ja) 2016-05-25
CN104066430A (zh) 2014-09-24
RU2014134845A (ru) 2016-03-20
EP2808018A4 (en) 2015-07-15
IN2014DN05972A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-26
CA2862602A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
HK1201209A1 (en) Therapeutic agent for diabetes
TWI621624B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
RU2627591C2 (ru) Терапевтический или профилактический агент для синдрома распада опухоли
KR101477480B1 (ko) 스테로이드 요법에 있어서의 부작용의 개선·억제용 조성물
JPH05506430A (ja) インスリン感性化剤類の高血圧治療のための使用
JP4569106B2 (ja) 臓器線維化抑制剤
KR20080010436A (ko) 당·지질 대사 이상의 예방 및/또는 치료약
US20210338648A1 (en) Methods and compositions for reducing serum uric acid
EP4122495A1 (en) Treatment or prevention method for chronic heart failure
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
JP2012072136A (ja) 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
US9241952B2 (en) Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin
WO2022059694A1 (ja) 腎機能改善用組成物
KR20130075442A (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
KR101311534B1 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
JP2020143037A (ja) 糖尿病合併心不全の治療用医薬組成物
WO2006064826A1 (ja) FBPase阻害剤を含有する医薬組成物
WO2023014748A1 (en) Nitrated fatty acids for the treatment of sickle cell disorders
HK40077878A (en) Treatment or prevention method for chronic heart failure
WO2016133069A1 (ja) 心不全の予防又は治療のための医薬
US20090227671A1 (en) Prevention and treatment of atherosclerosis with lithospermate B
JP2007091641A (ja) ２型糖尿病治療用の併用医薬
Chakera et al. P1. 09 The Effects of Rimonabant-Induced Weight Loss on Arterial Function and Glycaemia in Obese Adults with Type 2 Diabetes
JP2009062329A (ja) ホモピペラジン誘導体を有効成分とする糖化最終産物形成阻害剤
BR112015032410B1 (pt) uso de uma composição farmacêutica compreendendo inibidores de dpp-iv no preparo de um medicamento para prevenção ou tratamento de doenças renais